Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1).
Saved in:
| Title: | Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1). |
|---|---|
| Authors: | Santoni M; Oncology Unit, Macerata Hospital, Macerata, Italy., Roviello G; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. giandomenico.roviello@unifi.it., Grande E; Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Fiala O; Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic., Seront E; Department of Medical Oncology, Cliniques Universitaires Saint-Luc 1200, Brussels, Belgium., Molina-Cerrillo J; Hospital Ramón y Cajal, Madrid, Spain., Pichler R; Department of Urology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria., Myint ZW; Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0293, USA., Kucharz J; Department of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Warsaw, Poland., Kanesvaran R; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore., Büttner T; Department of Urology, University Hospital Bonn (UKB), 53127, Bonn, Germany., Pichler M; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Augenbruggerplatz 15, 8010, Graz, Austria., Basso U; Oncology 3 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy., Kopecky J; Department of Clinical Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czechia., Bourlon MT; Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Cerbone L; Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy., Buchler T; Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital Prague, Prague, Czech Republic., Pinto A; Medical Oncology Department, La Paz University Hospital, Madrid, Spain., de Liaño AG; Medical Oncology Department, CHU Insular-Materno Infantil, Las Palmas de Gran Canaria, Spain., Gianni C; Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Zgura A; Department of Obstetrics-Radiotherapy, Alexandru Trestioreanu Institute of Oncology, 'Carol Davila' University of Medicine and Pharmacy, Prof. Dr, Bucharest, Romania., Rescigno P; Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, UK., Ansari J; Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates., Caffo O; Medical Oncology Unit, Santa Chiara Hospital, Trento, Italy., Küronya Z; Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary., Vitale MG; Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy., Bhuva D; Department of Medical Oncology, Army Hospital Research and Referral, New Delhi, India., Catalano M; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy., Vau N; Urologic Oncology, Champalimaud Clinical Center, 1400-038, Lisbon, Portugal., Kopp RM; Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia., Buti S; Medical Oncology Unit, University Hospital of Parma, 43126, Parma, Italy., Bamias A; 2nd Propaedeutic Department of Internal Medicine, School of Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, Athens, Greece., Porta C; Interdisciplinary Department of Medicina, University of Bari 'Aldo Moro' and Division of Medical Oncology, A.O.U. Consorziale Policlinico Di Bari, Bari, Italy., Sunela K; Finnish Medicines Agency Fimea, Tampere, Finland., Massari F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni, 15, Bologna, Italy. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 May 27; Vol. 74 (7), pp. 225. Date of Electronic Publication: 2025 May 27. |
| Publication Type: | Journal Article; Comparative Study; Multicenter Study |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
